Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow UTHR by emailGet an email when UTHR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about UTHR, unsubscribe in one click. Privacy
📣 What UTHR Says Is Next
second half of 2026 · “United Therapeutics intends to present full results from the ADVANCE OUTCOMES study at an upcoming international conference and to submit an NDA for ralinepag to the FDA by the second half of 2026.”
Company press release, Mar 2, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full UTHR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UTHR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.